Want to join the conversation?
$PRGO Calendar 2015 2Q Call: Invested over $44MM in R&D. Consumer Healthcare and Branded Consumer Healthcare segment had combined net sales of $1.15Bil. New products for the consumer-facing business were $110MM. Expect to close GSK and Yokebe transaction in 3Q. Received 3 ANDA approval last week.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.